Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04844866|
Recruitment Status : Recruiting
First Posted : April 14, 2021
Last Update Posted : May 15, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Diffuse Large B-cell Lymphoma||Genetic: MB-CART2019.1 Drug: R-GemOx or BR plus polatuzumab vedotin||Phase 2|
This study should determine superiority of MB-CART2019.1 treatment compared to SoC therapy with R-GemOx (rituximab, gemcitabine and oxaliplatin) with respect to progression-free survival in second-line therapy in participants with R-R DLBCL, who are non-eligible for high-dose chemotherapy and autologous stem cell transplantation.
MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy®. Patients who are suitable for this study will be randomized 1:1 to either MB-CART2019.1 or SoC. Both treatment arms are unblinded.
MB-CART2019.1 arm: Single infusion of fresh formulation of 2.5 × 10^6 CAR-transduced autologous T cells. IMP is only to be administered after a lymphodepleting chemotherapy with fludarabine and cyclophosphamide. For MB-CART2019.1 production, patients will undergo a leukapheresis.
SoC arm: R-GemOx (8 cycles of 14 days each) or (10% of SoC arm) BR (Bendamustine/Rituximab) + polatuzumab vedotin (6 cycles of 21 days each).
The duration of the active part of the study for each individual participant from screening to the end of the 1-year follow-up after infusion of MB-CART2019.1 cells (experimental arm) or the start of SoC therapy (comparator arm) will be approximately 55 weeks. The LTFU in Year 2 after infusion of MB-CART2019.1 cells or the start of treatment in the comparator arm will not be part of the active part of the clinical study and will be reported separately.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||168 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||unblinded 1:1 randomization into IMP or SoC|
|Masking:||None (Open Label)|
|Official Title:||A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT|
|Actual Study Start Date :||August 18, 2021|
|Estimated Primary Completion Date :||December 31, 2023|
|Estimated Study Completion Date :||December 31, 2024|
Experimental: CAR T-cell MB-CART2019.1
Single infusion of 2.5 × 10^6 CAR-transduced autologous T cells per kg/body weight.
MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy® device.
Active Comparator: Standard of Care
Immunochemotherapy will be administered from the following 2 predefined regimens: R-GemOx (8 cycles of 14 days each) or BR plus polatuzumab vedotin (6 cycles of 21 days each). BR plus polatuzumab vedotin will be capped at a maximum of 10% of participants; i.e. a maximum of 8 participants will be randomised to the BR plus polatuzumab vedotin regimen.
Drug: R-GemOx or BR plus polatuzumab vedotin
Immunochemotherapy will be administered as per arm description.
Other Name: Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
- Progression-free survival [ Time Frame: up to 99 weeks after randomisation ]Determination of superiority of MB-CART2019.1 treatment compared to standard-of-care (SoC) therapy with R-GemOx with respect to progression-free survival in second-line therapy in participants with R-R DLBCL, who are non-eligible for high-dose chemotherapy and autologous stem cell transplantation (ASCT).
- Event-free survival [ Time Frame: up to 99 weeks after randomisation ]Progression of disease, start of new anti-cancer treatment, relapse or death of any cause
- Best complete response rate [ Time Frame: up to 99 weeks after randomisation ]To evaluate the safety and toxicity of MB-CART2019.1 compared to SoC therapy.
- Duration of complete response [ Time Frame: up to 91 weeks ]To evaluate the safety and toxicity of MB-CART2019.1 compared to SoC therapy.
- Overall survival [ Time Frame: up to 99 weeks after randomisation ]To evaluate the safety and toxicity of MB-CART2019.1 compared to SoC therapy.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Histologically proven DLBCL and associated subtypes, according to the WHO 2016 classification including:
- DLBCL not otherwise specified (NOS).
- High-grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (double hit lymphoma/triple hit lymphoma).
- High-grade BCL, NOS.
- Primary (thymic) large mediastinal BCL.
- Disease transformed from an earlier diagnosis of low-grade lymphoma (e.g. an indolent pathology such as follicular lymphoma, marginal zone lymphoma) into DLBCL with DLBCL disease progression subsequent to DLBCL directed systemic treatment.
Relapsed or refractory disease after first-line chemoimmunotherapy:
Refractory disease is defined as no CR to first-line therapy,
- PD as best response after at least 4 full cycles of R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone) cycles as first-line therapy.
- Stable disease (SD) after 6 R-CHOP cycles as first-line therapy.
- PR as best response after at least 6 R-CHOP cycles and biopsy-proven disease progression (except where prohibited due to comorbidities) within ≤ 12 months from the completion of the first-line therapy.
- Relapsed disease defined as complete remission to a first-line therapy followed by biopsy-proven disease progression (except where prohibited due to comorbidities) within ≤ 12 months from the completion of the first-line therapy.
- Participant must have received adequate first-line therapy containing at least the combination of an anthracycline-based regimen and rituximab (anti-CD20 monoclonal antibody). Local therapies (e.g. radiotherapies) will not be considered as line of therapy if performed during the same line of treatment.
- Archival paraffin-embedded tumour tissue acquired ≤ 3 years prior to screening for central pathology review to confirm DLBCL diagnosis and for analysis of CD20/CD19 expression must be made available for participation in this study. If archival paraffin-embedded tumour tissue is not available, fresh tumour tissue sample (preferred) or core-needle biopsy for this protocol must be made available.
Participants deemed ineligible to receive HDC followed by ASCT based on the treating physician's assessment and meeting the following criteria:
Age ≥ 18 years and
- Prior ASCT (as first-line consolidation) or
- Haematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) > 3.
Age ≥ 65 years and 1 of the criteria below:
- Prior ASCT (as first-line consolidation), or
- Comorbidities as assessed by an HCT-CI score > 3, or
- Impaired cardiac function (left ventricular ejection fraction (LVEF) < 50%), or
- Impaired renal function (creatinine clearance [CrCl] < 60 mL/min) as determined by MDRD (Modification of Diet in Renal Disease) formula or
- Impaired pulmonary function (diffusing capacity for carbon monoxide or forced expiratory volume in 1 second of 66% to 80%) or dyspnoea on slight activity, or
- Eastern Cooperative Oncology Group (ECOG) performance status > 1. Documentation of the reason for ineligibility for ASCT must be present in the participant's source data.
In addition, all participants must fulfil the following criteria:
- Age ≥18 years.
- Measurable disease according to Lugano criteria. The lesion must be positive on a positron emission tomography scan.
- Estimated life expectancy of > 3 months for other reasons than the primary disease.
Woman of childbearing potential (WOCBP) must agree to use highly effective contraceptive measures (Pearl index < 1) or practice true sexual abstinence from any heterosexual intercourse (True abstinence is only acceptable if it is in line with the preferred and usual life style of the participant.) or must have a vasectomised partner as the sole sexual partner (The vasectomised partner must have received medical assessment of the surgical success.) for at least 1 month before the study start, during the study and in the 12 months following the last dose of study treatment. A woman is considered a WOCBP, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Highly effective methods of contraception include hormonal contraceptives (oral, intravaginal, transdermal, injectable, implantable) and intrauterine devices or systems (e.g. hormonal and non-hormonal) and bilateral tubal occlusion. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A post-menopausal state is defined as no menses for 12 months without an alternative medical cause. WOBC must refrain from egg donation throughout the study until 12 months after the last dose of study treatment.
Men must agree to use 2 acceptable methods for contraception (e.g. spermicide and condom) or practice true sexual abstinence from any heterosexual intercourse (True abstinence is only acceptable if it is in line with the preferred and usual life style of the participant.), unless they are surgically sterile (meaning at least 2 consecutive analyses following vasectomy demonstrate absence of sperms in the ejaculate), during the study and in the 12 months following the last dose of study treatment. Men must furthermore refrain from sperm donation throughout the study until 12 months after the last administration of study treatment.
- In the opinion of the investigator, the participant must be able to comply with all study-related procedures, medication use and evaluations.
- Mental capacity and legal ability to consent to participation in the clinical study.
- Contraindications for R-GemOx and BR plus polatuzumab vedotin as judged by the treating physician.
- Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy.
- ECOG performance status > 2.
- Absolute neutrophil count < 1,000/μL (unless secondary to bone marrow involvement by DLBCL as demonstrated by bone marrow biopsy required for screening).
- Platelet count < 50,000/μL (unless secondary to bone marrow involvement by DLBCL as demonstrated by bone marrow biopsy required for screening).
- Absolute lymphocyte count < 100/μL.
- Participants who have CNS lymphoma involvement in present or past medical history.
- Known history of infection with human immunodeficiency virus or active infection with hepatitis B (hepatitis B surface antigen positive).
- Known history of infection with hepatitis C virus unless treated and confirmed to be polymerase chain reaction negative.
- Active infection with SARS-CoV-2.
- Known history or evidence of severely immunocompromised state; i.e. corticosteroid treatment > 10 mg/day for more than 6 months.
- Has received vaccination with live virus vaccines within 6 weeks prior to randomisation.
- Prior CD19 targeted therapy
- Known history or presence of seizure activities or on active antiseizure medications within the previous 12 months.
- Presence of CNS disease that, in the judgement of the investigator, may impair the ability to evaluate neurotoxicity.
- Known history or presence of autoimmune CNS disease, such as multiple sclerosis, optic neuritis or other immunologic or inflammatory disease.
- Known history or presence of cerebral vascular accident (CVA) within 12 months prior to randomisation. Note: In case of history of CVA > 12 months prior to leukapheresis, then the participant must not have any unstable or life-threatening neurological deficits.
- Participants with Richter's transformation or Richter's syndrome.
- Participants who are concurrently on any other experimental treatments or during the previous 4 weeks or 5-half-lives.
- Clinical heart failure with New York Heart Association class ≥ 2 or LVEF < 30%.
- Resting peripheral oxygen saturation < 90% on room air.
- Liver dysfunction as indicated by total bilirubin, aspartate aminotransferase and/or alanine aminotransferase > 5 × institutional upper limit of normal (ULN).
- Serum creatinine ≥ 2.0 × ULN or CrCl < 30 mL/min calculated according to the modified formula of MDRD.
- Pregnant or breast-feeding woman.
Prior history of malignancies other than DLBCL, unless the participant has been free of the disease for ≥ 3 years prior to screening. Exceptions to the ≥ 3-year time limit include history of the following:
- Basal cell carcinoma of the skin.
- Squamous cell carcinoma of the skin.
- Carcinoma in situ of the cervix.
- Carcinoma in situ of the breast.
- Carcinoma in situ of the bladder.
- Incidental histological finding of untreated localized (T1a or T1b) prostate cancer under surveillance.
- History of severe immediate hypersensitivity reaction against any drug or its ingredients/impurities that is scheduled to be given during study participation e.g. as part of the mandatory lymphodepletion protocol, premedication for infusion, or rescue medication/salvage therapies for treatment-related toxicities.
- Any medical condition likely to interfere with assessment of safety or efficacy of study treatment.
- Refusal to participate in CAR T long-term follow-up (LTFU).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04844866
|Contact: Gregor Zadoyan, Dr.||+49 2204 8306 ext email@example.com|
|Contact: Silke Holtkamp, Dr.||+49 2204 8306 ext firstname.lastname@example.org|
|Principal Investigator:||Peter Borchmann, Prof. Dr.||University Hospital Cologne|
|Responsible Party:||Miltenyi Biomedicine GmbH|
|Other Study ID Numbers:||
|First Posted:||April 14, 2021 Key Record Dates|
|Last Update Posted:||May 15, 2023|
|Last Verified:||May 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
CAR T cells
chimeric antigen receptor
Diffuse Large B-cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Immune System Diseases
Antineoplastic Agents, Immunological
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Alkylating